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Abstract Arginine-vasopressin (AVP) plays a determinant role in the normal ACTH response to stress in mammals. We cloned a human cDNA 
coding a 424 amino acid G-protein coupled receptor structurally related to the vasopressin/oxytocin receptor family . When expressed in COS cells, 
this receptor binds AVP with a high affinity (Kd = 0.55 f 0.13 nM) and is functionally coupled to phospholipase C. Competition studies with peptidic 
or non peptidic AVP analogues reveal that it is pharmacologically distinct from Vla and V2 AVP receptors and therefore it is designated V3. RT-PCR 
analysis shows that the human V3 receptor is expressed in normal pituitary and also in kidney, but is undetectable in liver, myometrium and adrenal 
gland. Northern blot analysis reveals a -4.8 kb messenger in human corticotropic pituitary adenomas. 
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1. Introduction 
The existence of a pituitary-specific receptor for arginine- 
vasopressin (AVP) participating in the stress-induced ACTH 
surge, has been surmised for many years [l]. AVP is a direct 
ACTH secretagogue which also exerts a synergistic effect on 
corticotropin releasing hormone (CRH) action in many species 
including in human [2]. 
The multiple actions of AVP are mediated by different mem- 
brane-bound receptors: the vascular Vla receptor coupled to 
phospholipase C (PLC) and the renal V2 receptor which acti- 
vates adenylate cyclase [3]. Several groups recently cloned these 
receptors in different species and identified a new subfamily 
including receptors for vasopressin, oxytocin and vasotocin 
[4-lo]. All the members of the AVP/oxytocin receptor family 
are G protein-coupled receptors with a classical structure made 
of a single polypeptide chain with seven transmembrane do- 
mains (TMD). 
AVP action on corticotroph cells is mediated by a specific 
receptor which activates PLC [l 1, 121. However, pharmacologi- 
cal studies suggest hat the pituitary-specific AVP receptor is 
distinct from both the Vla and the V2 receptors, hence its 
various designations as either Vlb or V3 113,141. 
We present here the structure, functional expression and 
tissue distribution of a cDNA encoding an AVP receptor 
cloned from a human pituitary corticotropic tumor responsible 
for a case of Cushing’s disease. This new receptor has the 
characteristics of a pituitary-specific PLC-coupled AVP recep- 
tor that should be recognized as the V3 AVP receptor. Surpris- 
ingly, it presents similar degrees of identity with the Vla, 
oxytocin and vasotocin receptors, and therefore is not closely 
related to the Vla receptor. 
*Corresponding author. Fax: (33) (1) 4441 2392. 
The nucleotide sequence data reported in this paper will appear in the 
EMBL, Genbank and DDBJ Nucleotide Sequence Databases under 
Accession Number L37112 (submitted the 10-25-94). 
2. Materials and methods 
2.1. cDNA library construction 
Total RNA was prepared by the guanidium/caesium chloride method 
[15] from a human (h) corticotropic adenoma obtained at surgery from 
a patient with Cushing’s disease. Poly(A)’ RNA was isolated using 
Dynabeads (Dynal). A cDNA library of 3 x lo6 primary recombinants 
was generated from 5 pg of poly(A)+ RNA using the ilZAPI1 cDNA 
cloning kit (Stratagene). 
2.2. Library screening 
A 1.5 kb EcoRI fragment containing the entire coding region of the 
human liver hVla receptor cDNA [lo] was used to screen the library 
under low stringency conditions (final wash: 2 x SSC, 0.1% SDS, 50” C 
for 30 min). One partial hV3 receptor cDNA clone was isolated and 
used for subsequent screening under standard conditions to identify 
full-length cDNAs. Nucleotide sequencing of both strands was done by 
the dideoxy chain-termination method using the Sequenase sequencing 
kit (United States Biochemicals Corp.). 
2.3. Transient expression in CO97 cells 
The cDNA coding for the entire sequence of the hV3 receptor was 
inserted as a 2.2 kbp EcoRI fragment into the expression vector pECE 
[16]. Transient expression of the hV3 receptor was obtained by transfec- 
tion of COS-7 cells, using the DEAE-Dextran method [lo]. Expression 
of the receptors was observed between day 2 and 10 after transfection. 
2.4. Radioligand binding assays 
Saturation binding experiments of hV3 receptors of confluent control 
and transfected COS-7 were performed as previously described [lo] 
with increasing concentrations of [3H]AVP ? 1 PM unlabeled AVP. 
Affinity and capacity of the hV3 receptors were calculated by a non- 
linear least square analysis program (Ebda Ligand; Elsevier-Biosoft, 
Cambridge, UK). Competition binding experiments were performed on 
COS-7 cells expressing hV3 or CHO cells expressing the Vla human 
receptor in the presence of 2 nM [‘HIAVP and increasing concentra- 
tions of competitors. AVP, oxytocin (Oxy), arginine-vasotocin (AVT) 
were from Sigma. The Vla antagonist d(CH&Tyr(Me)AVP, and the 
linear Vla antagonist Phenylacetyl-n-Tyr(Et)-Phe-Val-Asn-Lys-Pro- 
Tyr-NH, (TyrPhaa) were from Bachem. The non peptidic Vla antago- 
nist SR 49059 was provided by Dr. C. Serradeil-Le Gal, Sanofi Recher- 
the, Toulouse, France. The non peptidic rat Vla antagonist 0PC21268 
(batch number 93F92M), and the non peptidic V2 antagonist OPC 
31260 (batch number 93D96M) were provided by Dr. J.F. Liard, 
Otsuka America Pharmaceutical, Inc. Rockville, MD. The linear Vla 
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antagonists Phenylacetyl o-Tyr(Et)-Phe-Gln-Asn-Lys-Pro-Arg-NH, 
(PhaaGln), 4-l;ydroxy-Phenylacetyl-o_Sr(Me)-Phe-Gln-Asn-Arg- 
Pro-Am-NH 1 (OHPhaaGln). and tBaa-n-Tvr(Et)-Phe-Val-Asn-Lvs- 
Pro-A&NH, -@Baa), the VZ’&rtagonist d(CH,j,[d-Ile’-Ile“-Ala-N&l 
AVP (V2ag), and the VlaN3 antagonist Phenylacetyl-o-Tyr-Phe-Val- 
Asn-Arg-Pro-Arg-Arg-NH, were provided by Dr. M. Manning from 
the Medical College of Ohio in Toledo. All experiments were performed 
in duplicate and incubated 60 min at room temperature. After extensive 
washing, cells were solubilized in 0.5 ml of 0.2 N NaOH + 1% SDS and 
counted in a ,!I counter. 
2.5. Inositol phosphate (IP) determination 
Vasopressin-induced IP production was determined in non trans- 
fected and transfected COS-7 cells as previously described [17]. Cells 
were incubated with AVP (1 pM to 1 PM) in presence of 10 mM LiCl 
for 30 min. 
2.6. Northern blot analysis 
Pituitary tumors were collected at surgery and normal pituitaries 
were obtained at autopsy. Total and poly(A)’ RNAs were prepared as 
described in the library construction paragraph. RNAs were denatured 
with 15 mM CH,HgOH, separated on a 1% agarose/2.2 M formalde- 
hyde gel and transferred onto BAS-85 nitrocellulose sheet (Schleicher 
and Schuell). The membrane was hybridized under classical conditions 
with a 1.3 kb EcoRI fragment of hV3 receptor [18]. The probe encom- 
passing 5’ untranslated sequence and most of the coding region (up to 
TMD VI) was labeled by random priming with [c?P]dCTP. After the 
final wash the blot was autoradiographed on XAR film (Kodak) with 
intensifying screen (DuPont). 
2.7. RT-PCR analysis 
RT-PCR was performed according to standard protocols [18]. 
Briefly, random primed DNA were synthesized from 0.5 pg of total 
RNA with 20 units of MMLV reverse transcriptase (BRL). Half of the 
cDNA reaction was used for PCR with two oligonucleotides flanking 
TMS VI and VII. After 40 cycles of amplification 10% of the PCR 
products were analyzed on 2% agarose gel, blotted onto Nylon mem- 
brane and probed with an internal oligonucleotide. 
3. Results and discussion 
Biochemical and pharmacological studies performed in rat 
anterior pituitary primary cultures have shown the existence of 
a pituitary-specific receptor for AVP related to the Vl subfam- 
ily [13]. This receptor however is pharmacologically distinct 
from the already known Vla-receptor present in liver, brain, 
adrenals and in the vascular smooth muscle cells. For this 
reason, in an attempt to isolate a V3-receptor cDNA, we used 
a human Vla cDNA probe to screen a corticotropic pituitary 
adenoma library under low stringency conditions. This screen- 
ing resulted in the identification of a 4Skb cDNA, containing 
an open reading frame of 1,212 bp coding for a 424 amino acid 
protein (M, = 46,977) thereafter named hV3 (Fig. 1). 
The hydropathicity profile [19] of hV3 shows the typical 
features of a G protein-coupled receptor with seven putative 
transmembrane hydrophobic domains of 20-24 residues linked 
by three extracellular and three intracellular loops. The N- 
terminal region preceding the first TMD contains a single puta- 
tive N-linked glycosylation site at Asn’i. The third intracellular 
loop and the C-terminal tail contain numerous seryl and thre- 
onyl residues, many of which are in good sequence context for 
phosphorylation by protein kinase C or casein kinase II [20], 
and may therefore play a role in the regulation of receptor 
function. There is conservation of many of the cysteyl residues 
that are present in other members of the AVP/oxytocin recep- 
tor family. Some of them may form disulfide bridges (Cys 107 
and 186 between the extracellular loops 1 and 2) or anchor the 
C-terminal tail into the membrane after palmitoylation (Cys3”, 
Cys356 or CYSTIC) [21]. 
A search in the protein data bank (Swissprot) revealed 
marked sequence identities between hV3 and the other mem- 
bers of the AVPloxytocin receptor family (Fig. 2A). A relatively 
high degree of amino-acid sequence identity is observed with 
the human Vla, oxytocin and V2 receptors (45.5, 44.8 and 
37.3%, respectively), as well as with the animal members of this 
receptor family (46.2% with rat Vla , 37.8% with rat V2,44.3% 
with porcine oxytocin, 38.9% with porcine V2 and 45.7% with 
fish vasotocin receptors). The overall identity with other 7TMD 
receptors was below 15% (e.g. the human GnRH and gastrin/ 
cholecystokinin-B receptors (data not shown)). 
Amino acid identities between hV3 and other member of the 
AVP/oxytocin receptor family are not evenly distributed 
throughout the sequences. N- and C-terminal extremities show 
almost no identity except for a few residues adjacent to TMD 
I and VII. Within the TMD, identity varies from 36 to 87%, 
with the most conserved TMD being TMD II, III, VI, and VII. 
The putative common epitopes which delineate the binding site 
of the natural hormone AVP within the extracellular loops and 
TMD are not readily apparent. The first extracellular loop and 
the distal part of the second extracellular loop are strongly 
conserved within the AVPloxytocin receptor family, but se- 
quences within TMDs may also participate in forming the bind- 
ing site. It is interesting to note that two residues of hV3 (Ala” 
in TMD II and Va1209 in TMD V) are strictly conserved in all 
known vasopressin receptors, but are different in all vasotocin 
and oxytocin receptors. The sequences involved in G protein 
coupling and PLC activation are probably located in the second 
intracellular loop and the proximal and distal parts of the third 
intracellular loop [22]. These sequences are well conserved be- 
tween hV3 and the other receptors of the family coupled to PLC 
(50 to 78% identity) but diverge with those of the V2 receptor 
subtypes (23 to 30% identity). 
At the nucleotide level the strongest homology is found be- 
tween hV3 and the human oxytocin receptor. This special rela- 
tionship between hV3 and the oxytocin receptors was further 
assessed by constructing a phylogenetic tree from the progres- 
sive alignment of the receptor sequences (UPGMA method, 
Fig. 2B). This tree indicates that the hV3 receptor did not 
diverge recently from the hVla receptor as suspected, but in- 
stead evolved at an earlier stage from a common ancestor. 
Since the subtype classification of the hV3 was unknown, 
radioligand binding characterization was initiated with the na- 
tive hormone [3H]AVP itself in transiently transfected COS-7 
cells. These experiments confirm that hV3 binds AVP with a 
high affinity. Scatchard plotting (data not shown) indicates a 
single class of binding sites with a dissociation constant 
Kd = 0.55 + 0.13 nM, in good agreement with Kd values of 0.4 
nM to 4 nM previously reported in studies on human or animal 
pituitaries [14,23]. 
Competition binding experiments with the natural hormones 
AVP (K, = 0.72 f 0.17 nM), vasotocin (K, = 6.7 f 3.7 nM), and 
oxytocin (K, = 479 f 99 nM) reproduce the order of potency 
observed in autoradiographic studies performed by [3H]AVP 
displacement on human anterior pituitary tissues (vaso- 
pressin>vasotocin>>oxytocin) and show that hV3 does not 
belong to the oxytocin receptor subtype. The V2 specific antag- 
onists d(CH,),[u-Ile’-Ile4-Ala-NH,IAVP and 0PC3 1260 have a 
poor affinity for the hV3 receptor (K, = 499 + 200 nM, and 
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Fig. 1. Primary nucleotide and amino acid sequences of the human V3 receptor. Nucleotides are numbered from the putative starting codon. The 
putative transmembrane domains are underlined. The potential N-linked glycosylation site is shown by an asterisk. 
> 1000 nM respectively), which therefore does not belong pharmacological profiles of the pituitary and liver Vla recep- 
to the V2 subtype either. The affinity constants for hV3 and tors previously reported for the rat and pig, and readily distin- 
hVla receptors of various peptidic and non peptidic Vl ana- guish hV3 as a new subtype, significantly different from the 
logues are compared in Table 1. They are in agreement with the hVla subtype. 
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Fig. 2. (A) Alignment of the amino-acid sequences of the AVP/oxytocin family receptors. Human V3 (hV3), Vla (hVla), V2 (hV2), oxytocin (hOxy) 
receptors and the fish arginine-vasotocin (fAVT) are compared. Overlined regions correspond to TMD and boxed sequences are conserved in 4 of 
the 5 sequences. INT: internal, EXT: external. (B) Phylogenetic tree of the family of AVP/oxytoxin receptors. The nucleotide sequences include hV3, 
hVla, hV2, hOxy anf fAVT receptors and rat Vla (rvla), porcine lysine vasopressin (pV2), rat V2 (rV2) and porcine oxytocin (POxy). This tree 
was constructed using the UPGMA method. The topology of the tree and the branch lengths give an estimation of the evolutionary distances. 
Coupling of the hV3 receptor to intracellular signaling path- 
ways was explored in the transiently transfected COS cells. 
Nanomolar concentrations of AVP were found to stimulate an 
increase in phosphoinositide breakdown thus demonstrating a 
functional coupling to the PLC pathway (Fig. 3). The maximal 
5-fold stimulation of inositol phosphate production was de- 
tected in these cells after addition of 100 nM AVP (ECSo = 
1.63 f 0.32 nM). No stimulation of CAMP production was de- 
tected in these cells after addition of 1 PM AVP (data not 
shown). Taken together, these data demonstrate that the hV3 
cDNA encodes an AVP receptor with binding properties dis- 
tinct from those of the Vla and V2 receptor subtypes and 
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Fig. 3. Vasopressin-induced stimulation of total IP production. IP production was determined in non transfected (0) and transfected @) COS-7 cells 
in presence of indicated concentrations of AVP. Results are expressed as the ratio of the cpm in cells exposed to the buffer (basal value) and represent 
the mean f S.E.M. of three different experiments performed in triplicate. 
signaling properties identical to those of the Vla and oxytocin 
receptors. Accordingly and also for phylogenetic reasons, we 
decided to designate it as the hV3 receptor. 
Prior pharmacological studies suggested that hV3 receptor 
expression was restricted to the anterior pituitary and possibly 
limited to the corticotroph cells [23]. Consistent with these data, 
a predominant 4.8 kb mRNA was detected by Northern blot 
analysis of two corticotropic pituitary adenomas responsible 
for Cushing’s disease (Fig. 4A). Given the low level of expres- 
sion of hV3 receptor in these homogeneous populations of 
corticotroph cells, its tissue distribution was further analysed 
by RT-PCR. As shown in Fig. 4B, a PCR product of the 
expected size was present in three different normal human 
pituitaries whereas no such signal was detectable in liver, adre- 
nals or myometrium, which express the Vla and oxytocin re- 
ceptors, and in a range of other human tissues including brain, 
spleen, muscle, lung and foreskin fibroblasts (data not shown). 
Unexpectedly, a faint but distinct signal was detected in kidney, 
which also expresses Vla [24] and V2 receptors [5]. Thusfar, the 
kidney is the only organ to express all three known types of 
AVP receptors. The precise localization of hV3 mRNA in the 
pituitary and of each receptor in the kidney should be examined 
by in situ hyridization. 
The V3-pituitary receptor plays a major role in the regulation 
Table 1 
Comparison of the affinity (K, in nM) of AVP and structural analogs for the human Vla and V3 receptors 
Compound hV3R hVla R ratio V3Nla 
Natural hormones 
1. AVP 0.72 1.66 0.42 
2. Vasotocin 5.4 5.0 1.1 
3. Oxytocin 391 87.1 4.5 
V2 antagonists 
4. d(CH,),[D-Be’-Ile4-Ala-NH,JAVP 499 52.9 9.4 
5. OPC31260 > 1000 142 >7 
Vl analogues 
6. d(CH,),Tyr(Me)AVP 64.3 1.59 40.4 
7. Phenylacetyl-D-Tyr(Et)-Phe-Val-Asn-Lys-Pro-Tyr-NH~ 80.3 2.37 33.9 
8. Phenylacetyl-D-Tyr(Et)-Phe-Gln-Asn-Lys-Pro-Arg-NH~ 10.7 0.79 13.5 
9. 4-hydroxy-Phenylacetyl-D-Tyr(Me)-Phe-Gln-Asn-Arg-Pro-Arg-NH~ 1.24 0.45 2.8 
10. tBaa-D-Tyr(Et)Phe-Val-Asn-Lys-Pro-Arg-NH, 113 0.79 143 
11. SR 49059 38.2 0.97 39.4 
12. 0PC21268 > 1000 > 1000 _ 
13. Phenylacetyl-D-Tyr-Phe-Val-Asn-Arg-Pro-Arg-Arg-NH~ 4.7 0.58 8.1 
Affinity constants for the hV3 receptor were derived from competition experiments performed in the present study with 2 nM [‘H]AVP and COS-7 
cells transfected with the hV3 clone. Affinity constants for the Vla receptors were obtained with the Vla ligand [‘ZSI]Phenylacetyl-o-Tyr(Et)-Phe-Val- 
Asn-Lys-Pro-Tyr-NH, and CHO cells transfected with an Vla clone [lo]. The protocol for these experiments was as previously described [lo]. 
Each value represents the mean + S.E.M. of at least 3 different experiments. K, values were calculated according to the Cheng and Prusoff equation, 
K, = IC,,,/l+(L,JK,). 
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Fig. 4. Tissue expression of the hV3 receptor mRNA. (A) Northern blot 
analysis of two corticotropic adenomas (C2 and C4). Each lane con- 
tains 2 pg of poly(A)’ RNA. The position of hV3 mRNA is indicated 
by the arrow and the position of the 28s and 18s rRNA of an adjacent 
lane are indicated bv dashes. (B) hV3 recentor RT-PCR analvsis of total 
RNA from three n&ma1 pituitaries (Hl: H2, and H3), non-pregnant 
(Ml) and pregnant (M2) myometrium, adrenal (Ad), liver (L) and 
kidney (K,). The amplified PCR product is shown by the arrow. 
of ACTH secretion through its potentiating effect on CRH- 
stimulation. It is specifically involved in the corticotropic re- 
sponse to stress in many species including man where AVP is 
clearly required for a full corticotropic response. Elegant phys- 
iological studies on ACTH regulation in animals have demon- 
strated the role of AVP in the response to stress: whereas 
immunization against CRH strongly diminishes both stress- 
induced and basal ACTH secretion, immunization against AVP 
only blunts the stress-induced ACTH surge without affecting 
the basal level of circulating ACTH [l, 251. 
Stable cell lines expressing the hV3 receptor will be instru- 
mental to develop specific V3 analogues with either agonist or 
antagonist activities. Such molecules should provide a new 
pharmacological approach to assess and manipulate an essen- 
tial, endocrine, component of the response to stress. 
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